Related Experiment Videos

Pharmacologic therapy for osteoarthritis--the era of disease modification

David J Hunter1

  • 1Rheumatology Department and Northern Clinical School, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. david.hunter@sydney.edu.au

Nature Reviews. Rheumatology
|November 17, 2010
PubMed

Insights

Developing disease-modifying osteoarthritis drugs (DMOADs) is crucial for treating osteoarthritis (OA). This review discusses promising DMOADs in development and future research challenges for OA treatment.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Biomedical Engineering

Background:

  • Osteoarthritis (OA) is a widespread, disabling joint disease with limited therapeutic options.
  • Current OA treatments primarily manage symptoms, not disease progression.
  • There is a critical need for therapies that modify OA's structural damage.

Purpose of the Study:

  • To review the concept of disease modification in OA.
  • To discuss challenges in discovering and developing disease-modifying OA drugs (DMOADs).
  • To highlight promising DMOAD candidates in late-stage development.

Main Methods:

  • Literature review of OA disease modification strategies.
  • Analysis of DMOADs currently in Phase II and III clinical trials.
  • Discussion of research gaps and future directions in OA drug development.

Main Results:

  • Several targeted agents show promise as DMOADs.
  • Mature development phases include agents beyond preclinical stages.
  • Challenges in DMOAD development include identifying appropriate targets and endpoints.

Conclusions:

  • Developing effective DMOADs is a key focus in OA research.
  • Promising agents are advancing through clinical trials.
  • Addressing research challenges is vital for future OA treatment advancements.

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Principles of Drug Action01:24

Principles of Drug Action

Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...